Pfizer (PFE) said Thursday that Talzenna plus Xtandi combination improved overall survival in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations, during a phase 3 trial.
The combination showed "a statistically significant and clinically meaningful improvement in overall survival," compared with placebo plus Xtandi, the company said.
The safety profile of the combination was generally consistent with the known safety profile of each medicine, Pfizer said.
The data have been shared with global health authorities, including the US Food and Drug Administration, to support potential updates of the approved labels for Talzenna, it added.
Price: 25.58, Change: +0.11, Percent Change: +0.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.